Oura reaches $11 billion valuation with new $900 million fundraise

Oura reaches  billion valuation with new 0 million fundraise


The Oura Ring 4

Courtesy: Oura

Oura said Tuesday that it raised over $900 million in a new Series E funding round, bringing the company’s valuation to $11 billion.

The fundraise, led by Fidelity Management & Research Company, also includes new investor ICONIQ and contributions from Whale Rock and Atreides.

“With this investment, we will accelerate innovation, expand our global reach, and set a new standard for what wearables can achieve in advancing preventive health,” said CEO Tom Hale in a statement.

The Finnish company, which ranked No. 23 on CNBC’S 2025 Disruptor 50 List, has raised approximately $1.5 billion, according to a release.

Known for its Oura Rings, the company competes with other smart ring makers like Samsung and RingConn, as well as fitness-focused devices from Whoop and Garmin.

Oura announced in September that it has sold over 5.5 million Oura Rings since the product’s launch in 2015, a significant jump from 2.5 million rings announced in June 2024. The company reported revenue of over $500 million in 2024, more than double from the year prior, and expects to reach $1 billion in sales this year.

Looking to broaden further in the wearable category, Oura has also been expanding its features to compete with more general wearable devices like Apple or Samsung watches.

Along with its new Oura Ring 4 Ceramic, the company recently unveiled Health Panels, a blood testing feature that allows users to schedule and view their lab results directly in the Oura App.

Users can keep track of up to 50 biomarkers and can receive their health data summary as well as diet or activity suggestions from Oura’s AI-powered Advisor.

The ring maker also partnered with Dexcom, a leader in glucose monitoring technology, late last year to integrate Dexcom glucose data with biometrics collected by Oura so users can monitor their glucose levels.

“We’re proud to be building not just a product, but a global movement toward proactive health—helping people understand their bodies, make better lifestyle decisions, and connect more effectively with their healthcare providers,” Hale said.



Source

Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
Health

FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images U.S. cattle ranchers will soon have a new […]

Read More